Intravenous Chlorothiazide for Acute Heart‑Failure Decongestion

Indications & Clinical Context

The American College of Cardiology (ACC) and the American Heart Association (AHA) recommend intravenous chlorothiazide for sequential nephron blockade when loop diuretics alone fail to achieve adequate decongestion in acute heart failure or severe fluid overload. 1
It is indicated in diuretic‑resistant states, defined as inadequate urine output or persistent clinical congestion despite escalating intravenous loop‑diuretic doses (e.g., furosemide, bumetanide, torsemide). 1
The drug should be used in addition to a loop diuretic (not as a substitute) to block sodium reabsorption at multiple nephron sites. 1
Hospitalized patients with acute decompensated heart failure and refractory volume overload despite optimized loop‑diuretic therapy are appropriate candidates. 2

Standard dose: 500 mg–1 g IV administered once or twice daily as a slow infusion. 1
Maximum daily dose: 2 g per day. 1
Administration principle: Always given concurrently with a loop diuretic to achieve synergistic natriuresis. 1

All other thiazide and thiazide‑like agents are available only in oral formulations (hydrochlorothiazide, chlorthalidone, metolazone, indapamide). 1
Representative oral dosing ranges (for reference only):
- Hydrochlorothiazide – 25–100 mg once or twice daily (max 200 mg/day).
- Chlorthalidone – 12.5–50 mg once daily (max 100 mg/day).
- Metolazone – 2.5–10 mg once or twice daily (max 20 mg/day).
- Indapamide – 2.5 mg once daily (max 5 mg/day).
  *These dosing tables are derived from ACC and AHA publications. 1

Rapid onset of action by bypassing gastrointestinal absorption, which may be compromised in patients with bowel wall edema from severe heart failure. 2
Predictable bioavailability ensures reliable drug delivery in critically ill patients unable to tolerate oral medications. 2
Synergistic natriuretic effect: When combined with a loop diuretic, intravenous chlorothiazide produces significantly greater sodium excretion than either agent alone. 1

Oral thiazide‑like agents (chlorthalidone, metolazone, indapamide) cannot substitute for intravenous chlorothiazide in acute settings that require immediate sequential nephron blockade; chlorothiazide remains the sole IV thiazide option. 1

Evidence level for the above recommendations is not explicitly graded in the cited ACC/AHA sources.